SOURCE: Century Capital Markets

December 19, 2011 07:30 ET

Coronado Biosciences to Begin Trading on NASDAQ Today

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CENTURY CAPITAL MARKETS.

NEW YORK, NY--(Marketwire - Dec 19, 2011) - Coronado Biosciences, Inc. (OTCBB: CNDO) (NASDAQ: CNDO) announced on Thursday that they have been approved for listing on the NASDAQ Capital Market under the symbol CNDO.

Coronado joins other biotechnology companies such as Dendreon Corp (NASDAQ: DNDN), Pharmasset, Inc (NASDAQ: VRUS) and Gilead Sciences (NASDAQ: GILD) on the NASDAQ, the world's largest exchange company.

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activate s natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Century Capital Markets twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information